Monday, February 11, 2008

Quark + Boulder = siRNA Clinical Candidates

Thank you for the emails re: last weeks post on Juvaris BioTherapeutics. This week I am continuing the theme of highlighting more of the private companies who though not headquartered in Colorado have a meaningful presence. One such company is Quark Pharmaceuticals who though headquartered in Freemont, CA maintains their development unit Boulder.

Quark Pharmaceuticals is a development-stage pharmaceutical company engaged in discovering and developing novel therapeutic RNAi drug candidates. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development and includes:

  • A proprietary gene discovery platform (BiFAR™) and algorithm for optimizing siRNA design
  • Novel siRNA structures and chemistry that Quark believes provide freedom to operate in the crowded siRNA intellectual property arena for its future product pipeline
  • The ability to deliver siRNA locally and systemically to organs including eye, ear, kidney, lung, spinal cord and bone marrow
Quark has a robust product portfolio including two clinical, one pre-IND and six preclinical candidates in development. Its lead product candidates are RTP801i-14, an siRNA molecule in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration that is licensed to Pfizer on an exclusive worldwide basis. AKIi-5 is a Phase I, siRNA molecule, delivered systemically, for the prevention of acute kidney injury / acute renal failure following major cardiac surgery, and AHLi-11, a pre-IND siRNA molecule for the prevention of chemotherapy and noise-induced hearing loss.

***NOTE*** Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!

If you enjoyed this post get free email or RSS updates (here).

No comments: